Advocacy group representing U.S. biopharmaceutical and biotechnology companies, promoting policies that enable drug discovery and broader patient access to safe, effective medicines. Focuses on free-market access (opposing price controls), strong intellectual-property protections, transparent regulation, and unfettered information flow to patients.